Showing 3491-3500 of 5773 results for "".
- OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet AMDhttps://modernod.com/news/olix-pharmaceuticals-doses-first-patient-in-clinical-trial-for-rnai-therapeutic-olx10212-for-dry-and-wet-amd/2481494/OliX Pharmaceuticals announced that the first patient has been successfully dosed in a phase 1 clinical trial (
- Haag-Streit Launches New Corneal Ectasia Display for the Eyestar 900https://modernod.com/news/haag-streit-launches-new-corneal-ectasia-display-for-the-eyestar-900/2481487/Haag-Streit announced the launch of a new corneal ectasia display for the Eyestar 900 swept-source-based precision OCT analyzer. The new display features OCT-based topography for elevation information of the cornea front and back surface, as well as pachymetry maps
- Aurion Biotech Receives Approval in Japan for First Allogeneic Cell Therapy to Treat Corneal Endothelial Diseasehttps://modernod.com/news/aurion-biotech-receives-approval-in-japan-for-first-allogeneic-cell-therapy-to-treat-corneal-endothelial-disease/2481486/Aurion Biotech announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its novel cell therapy, Vyznova, for the treatment of bullous keratopathy of the cornea. The company believes this is the first regulatory approval in the world fo
- Visus Therapeutics Completes Enrollment in BRIO-I Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-completes-enrollment-in-brio-i-a-phase-3-clinical-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481483/Visus Therapeutics announced it has completed patient enrollment and the last visit had been conducted in BRIO-I, a phase 3 trial for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. “We are thrilled to have reache
- The American Diabetes Association and Genentech Partner to Increase Equitable Access to Eye Health Carehttps://modernod.com/news/the-american-diabetes-association-and-genentech-partner-to-increase-equitable-access-to-eye-health-care/2481482/The American Diabetes Association (ADA) and Genentech announced a new partnership as part of the ADA’s Health Equity Now work to tackle access to screening and treatment for eye diseases that affect the diabetes communit
- NovaBay Pharmaceuticals Launches Avenova Eye Health Support to Comfort Dry Eyes and Promote Eye Healthhttps://modernod.com/news/novabay-pharmaceuticals-launches-avenova-eye-health-support-to-comfort-dry-eyes-and-promote-eye-health/2481480/NovaBay Pharmaceuticals announced the launch of OTC Avenova Eye Health Support oral supplement featuring a combination of MaquiBright, a nutrient-rich, antioxidant-dense extract of the superfruit maqui berry, and natural triglyceride omega-3 oils, designed to comfort dry eyes and s
- Aviceda Submits Investigational New Drug Application for AVD-104 for the Treatment of GA Associated with AMDhttps://modernod.com/news/aviceda-submits-investigational-new-drug-application-for-avd-104-for-the-treatment-of-ga-associated-with-amd/2481477/Aviceda Therapeutics announced that it has submitted an investigational new drug (IND) application to the FDA. The IND supports the use of its lead intravitreal ocular asset, AVD-104 (a novel glycan-coated nanoparticle), for the treatment of GA secondary to AMD. Aviceda previously announced
- RG6501 (OpRegen) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summithttps://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit/2481476/Lineage Cell Therapeutics announced that results from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the
- Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Diseasehttps://modernod.com/news/kuria-therapeutics-completes-fda-pre-ind-consultation-for-topical-nrf2-activator-for-corneal-endothelial-disease/2481475/Kuria Therapeutics has announced it has completed a pre-investigational new drug (IND) interaction with the FDA and received positive feedback on its development program for KTX-1161 for corneal endothelial disease. KTX-1161 is a topical ophthalmic solution formulation of SCO-
- BioCareSD and AllyRetina GPO Partner to Help Retina Providers Improve Patient Care and Increase Efficiencyhttps://modernod.com/news/biocaresd-and-allyretina-gpo-partnership-to-help-retina-providers-improve-patient-care-and-increase-efficiency/2481473/BioCareSD announced its partnership with AllyRetina. Debuting at the American Society of Retina Specialists (ASRS) 24th Annual Business of Retina conference this week, AllyRetina will serve its GPO members through its physician leadership, a seasoned management team, and innovative tools and